Featured Research

from universities, journals, and other organizations

Virus may act as 'evolution-proof' biopesticide against malaria

Date:
August 21, 2010
Source:
American Society for Microbiology
Summary:
A naturally occurring virus in mosquitoes may serve as a "late-life-acting" insecticide by killing older adult mosquitoes that are responsible for the bulk of malaria transmission.

A naturally occurring virus in mosquitoes may serve as a "late-life-acting" insecticide by killing older adult mosquitoes that are responsible for the bulk of malaria transmission. The researchers from Johns Hopkins University and the Johns Hopkins Malaria Research Institute, Baltimore, Maryland, detail their findings in the August 2010 issue of the Journal of Virology.

Malaria infects hundreds of thousands of people each year and is the cause of over a million deaths worldwide. Insecticides are one of the main strategies currently used to control malaria transmission, however, evolving resistance to such therapies continues to impact such efforts. "Late-life-acting" insecticides (LLAIs) are now being examined as a new approach for controlling malaria as they selectively kill older mosquitoes that spread the disease, while younger mosquitoes survive just long enough to reproduce.

"Reproduction allows for relaxation of evolutionary pressures that select for resistance to the agent," say the researchers. "If resistance alleles exert fitness costs, there are theoretical scenarios under which resistance is not expected to evolve, leading some to provocatively term LLAIs as 'evolution-proof'."

Densonucleosis viruses (or densoviruses [DNVs]) are naturally occurring parvoviruses that have been identified in multiple mosquito species. Some DNVs typically infect during the larval stage and are lethal, however, in this study researchers suggest that the Anopheles gambiae densovirus (AgDNV) may infect at low levels during early life and replicate to lethal levels at adult age. Analysis following infection showed that although AgDNV levels increased modestly during larval development they still replicated slower resulting in significantly decreased virus levels during this stage. Additionally, virus levels greatly increased in 7-to-10-day-old adults.

"Ultimately, we expect that a properly engineered LLAI AgDNV can be deployed in the field to significantly modulate malaria transmission," say the researchers.


Story Source:

The above story is based on materials provided by American Society for Microbiology. Note: Materials may be edited for content and length.


Journal Reference:

  1. Ren et al. Potential for the Anopheles gambiae Densonucleosis Virus To Act as an "Evolution-Proof" Biopesticide. Journal of Virology, 2010; 84 (15): 7726 DOI: 10.1128/JVI.00631-10

Cite This Page:

American Society for Microbiology. "Virus may act as 'evolution-proof' biopesticide against malaria." ScienceDaily. ScienceDaily, 21 August 2010. <www.sciencedaily.com/releases/2010/08/100820133238.htm>.
American Society for Microbiology. (2010, August 21). Virus may act as 'evolution-proof' biopesticide against malaria. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2010/08/100820133238.htm
American Society for Microbiology. "Virus may act as 'evolution-proof' biopesticide against malaria." ScienceDaily. www.sciencedaily.com/releases/2010/08/100820133238.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins